BiotechTube

tadalafil + tadalafil + tadalafil + tadalafil + placebo

Phase 2/3Completed
0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Benign Prostatic Hyperplasia

Conditions

Benign Prostatic Hyperplasia

Trial Timeline

Aug 1, 2006 → Oct 1, 2008

NCT ID
NCT00384930

About tadalafil + tadalafil + tadalafil + tadalafil + placebo

tadalafil + tadalafil + tadalafil + tadalafil + placebo is a phase 2/3 stage product being developed by Eli Lilly for Benign Prostatic Hyperplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT00384930. Target conditions include Benign Prostatic Hyperplasia.

What happened to similar drugs?

10 of 20 similar drugs in Benign Prostatic Hyperplasia were approved

Approved (10) Terminated (1) Active (9)
✅Tadalafil + Placebo + Alpha1 BlockerEli LillyApproved
✅Mirabegron + Placebo + Tamsulosin HydrochlorideAstellas PharmaApproved
✅Tamsulosin hydrochloride + Solifenacin succinateAstellas PharmaApproved
✅Tamsulosin OCASAstellas PharmaApproved
✅Tamsulosin OCAS + PlaceboAstellas PharmaApproved
✅Tamsulosin + Finasteride + PlaceboAstellas PharmaApproved
✅ErtapenemMerckApproved

Hype Score Breakdown

Clinical
15
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00384930Phase 2/3Completed
NCT00125918Phase 3Completed

Competing Products

20 competing products in Benign Prostatic Hyperplasia

See all competitors
ProductCompanyStageHype Score
Tadalafil + PlaceboEli LillyPhase 3
40
5 mg Tadalafil + Placebo + 0.2 mg TamsulosinEli LillyPhase 3
40
Placebo + tadalafilEli LillyPhase 3
40
Tadalafil + Placebo + Alpha1 BlockerEli LillyApproved
43
Placebo tamsulosin hydrochloride OCAS 0.4 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg + Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg + tamsulosin hydrochloride OCAS 0.4 mg + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg) + tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)Astellas PharmaPhase 3
40
Mirabegron + Placebo + Tamsulosin HydrochlorideAstellas PharmaApproved
43
ASP4901 + Tamsulosin + PlaceboAstellas PharmaPhase 2
35
Tamsulosin hydrochloride + Solifenacin succinateAstellas PharmaApproved
43
Tamsulosin OCASAstellas PharmaApproved
43
Tamsulosin OCAS + PlaceboAstellas PharmaApproved
43
Tamsulosin + Finasteride + PlaceboAstellas PharmaApproved
39
Tadalafil + PlaceboEli LillyPhase 2
35
TadalafilEli LillyPhase 1
29
Tadalafil + Placebo + TamsulosinEli LillyPhase 3
40
Tadalafil 2.5 mg + Tadalafil 5 mg + PlaceboEli LillyPhase 2
35
Tadalafil 5 mg + Placebo tablet + Tamsulosin + Placebo capsuleEli LillyPhase 3
40
Tadalafil + PlaceboEli LillyPhase 3
40
Tadalafil + Placebo + TamsulosinEli LillyPhase 2
35
Tadalafil + PlaceboEli LillyPhase 3
40
Tadalafil + Placebo + FinasterideEli LillyPhase 3
40